The Promise and the Price: Exploring the Benefits and Costs of GLP-1 Medications

In recent years, medications such as Ozempic (semaglutide) and Mounjaro (tirzepatide) have captured public attention – not only for their role in managing type 2 diabetes, but also for their profound effects on weight loss. These drugs belong to a class of medications known as GLP-1 receptor agonists, originally developed to help regulate blood sugar levels. But their story has quickly evolved beyond diabetes management.

This article takes a balanced look at the benefits and potential trade-offs of GLP-1 medications, drawing from current research and public health data. It is intended to inform, not advise, and to support thoughtful conversations between individuals and their healthcare providers.

What are GLP-1 medications?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone that helps control blood sugar, slows gastric emptying, and increases feelings of fullness. GLP-1 receptor agonists mimic this hormone, leading to improved blood sugar control and, in many cases, significant weight loss.

Ozempic and Wegovy (both containing semaglutide, but marketed differently for diabetes and obesity), and Mounjaro (tirzepatide, which also affects another hormone called GIP), are currently among the most well-known drugs in this class.

Key Benefits

Blood Sugar Control

Originally approved to treat type 2 diabetes, GLP-1 medications help the body release insulin in a glucose-dependent way. This means they reduce the risk of blood sugar dropping too low – a common problem with some older diabetes medications. A review in The Lancet noted that semaglutide “improves glycaemic control and reduces cardiovascular events” in people with type 2 diabetes.

Clinically Significant Weight Loss

Perhaps the most headline-grabbing benefit is the impact on weight. According to a 2021 trial published in The New England Journal of Medicine, participants using semaglutide for weight management lost an average of 14.9% of their body weight over 68 weeks – compared to 2.4% in the placebo group (source).

Mounjaro has shown even more pronounced effects. In a 2022 study, tirzepatide led to an average weight loss of 15% to 21% depending on the dose.

Reduced Risk of Cardiovascular Events

For people with diabetes and existing cardiovascular risk, semaglutide has demonstrated a reduction in major events like heart attacks and strokes. The SUSTAIN-6 trial reported a 26% relative risk reduction in major adverse cardiovascular events with semaglutide compared to placebo.

Potential Costs and Trade-Offs

Side Effects

Common side effects include nausea, vomiting, diarrhoea, and constipation. These are often most noticeable when starting the medication and can diminish over time. However, more serious side effects, such as pancreatitis and gallbladder issues, have also been reported in rare cases. According to the FDA, both Ozempic and Mounjaro carry warnings for these risks.

Cost and Access

One of the most significant concerns around these medications is cost. In the UK, Ozempic is approved for NHS use in certain cases of type 2 diabetes, but not currently for obesity alone. Wegovy, a higher-dose version of semaglutide, was approved for obesity by NICE in 2023 under specific conditions, such as use in specialist weight management services.

In private healthcare settings, costs can be substantial. A single month’s supply of semaglutide or tirzepatide can range from £150 to £300 in the UK, and significantly more in the US. These prices raise important questions about accessibility and health equity.

Uncertain Long-Term Effects

While short-term safety is well documented, questions remain about the long-term use of GLP-1 medications – especially in populations using them primarily for weight loss. For example, there are early concerns about potential muscle loss during rapid weight reduction, although further study is needed to confirm this.

A JAMA article in 2023 highlighted how weight loss from GLP-1 drugs may include both fat and lean body mass loss, which could have health implications over time.

Social and Psychological Impacts

The popularity of GLP-1 drugs has extended far beyond clinical settings, becoming a topic of interest in celebrity culture and social media. While this visibility can help reduce stigma around weight and chronic conditions, it also risks creating unrealistic expectations or encouraging off-label use without medical supervision.

There’s also growing discussion about how GLP-1s might affect eating behaviours and emotional relationships with food. A 2024 New York Times article profiled individuals who reported losing the “pleasure of eating” while on medication – a result of altered appetite cues.

Final Thoughts

GLP-1 medications like Ozempic and Mounjaro are changing the landscape of chronic disease management and weight loss. The benefits are well-documented: improved metabolic health, reduced cardiovascular risks, and meaningful weight reduction. However, the financial costs, potential side effects, and unanswered long-term questions mean that these drugs aren’t a universal solution.

For individuals considering these medications, the decision should be made in partnership with a healthcare provider – taking into account not only physical health, but emotional wellbeing, lifestyle, and access to care.

The conversation around GLP-1s is still evolving. As more research emerges and regulations adapt, public understanding and responsible use will be essential in realising the potential of these powerful tools.

Refresh This Page